Effects of different types of allogeneic hematopoietic stem cell transplantation donors on Philadelphia chromosome-positive acute lymphoblastic leukemia during the tyrosine kinase inhibitor era: A systematic review and meta-analysis.
Journal
Hematology/oncology and stem cell therapy
ISSN: 2589-0646
Titre abrégé: Hematol Oncol Stem Cell Ther
Pays: Saudi Arabia
ID NLM: 101468532
Informations de publication
Date de publication:
04 Apr 2023
04 Apr 2023
Historique:
received:
14
06
2021
accepted:
23
09
2021
medline:
10
4
2023
pubmed:
9
11
2021
entrez:
8
11
2021
Statut:
epublish
Résumé
Matched donor (MD) allogeneic hematopoietic stem cell transplantation (allo-HSCT) is currently the preferred choice of treatment for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph Studies in EMBASE and MEDLINE between inception and December 2020 were identified using search terms related to "Ph Fourteen cohort studies were identified for the meta-analysis. Haploidentical (HID)-HSCT for Ph This systematic review and meta-analysis showed that HID-HSCT is as effective as MD-HSCT in Ph
Sections du résumé
BACKGROUND
BACKGROUND
Matched donor (MD) allogeneic hematopoietic stem cell transplantation (allo-HSCT) is currently the preferred choice of treatment for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph
METHODS
METHODS
Studies in EMBASE and MEDLINE between inception and December 2020 were identified using search terms related to "Ph
RESULTS
RESULTS
Fourteen cohort studies were identified for the meta-analysis. Haploidentical (HID)-HSCT for Ph
CONCLUSION
CONCLUSIONS
This systematic review and meta-analysis showed that HID-HSCT is as effective as MD-HSCT in Ph
Identifiants
pubmed: 34743893
pii: S1658-3876(21)00091-1
doi: 10.1016/j.hemonc.2021.09.007
doi:
Substances chimiques
Tyrosine Kinase Inhibitors
0
Protein Kinase Inhibitors
0
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM